Hercules Capital Provides $30MM Debt Facility to HiberCell

HiberCell, a biotechnology company developing therapeutics for the prevention of cancer relapse and metastasis, closed on a $30 million debt facility with Hercules Capital. In addition, HiberCell completed a Series B financing round for gross proceeds of $67.4 million.

May 20, 2021 Alan Rigby | ARCH Venture Partners | Bristol-Myers Squibb | Hercules Capital | HiberCell | Huizenga Capital Management | Magnetic Ventures | Monashee Investment Management | Mount Sinai Innovation Partners | Rene Mora | Tekla Capital Management | Trinitas Capital Ian Koplin

Hercules Capital and SVB Provide $60MM Term Loan to SCYNEXIS

SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.

May 17, 2021 Armentum Partners | Bryan Jadot | Hercules Capital | Marco Taglietti | SCYNEXIS | Silicon Valley Bank | Tom Gordon Ian Koplin

Hercules Capital and SVB Provide $75MM Loan Facility to Geron

Hercules Capital and Silicon Valley Bank provided a loan facility of up to $75 million for Geron, supporting the company with access to non-dilutive financial resources to support its imetelstat development program.

October 2, 2020 Geron | Hercules Capital | Imetelstat | Olivia K. Bloom | Silicon Valley Bank Phil Neuffer

SBA Gives ‘Green Light’ for Hercules Capital’s Third SBIC Application

The U.S. Small Business Administration issued a “green light” or “go forth” letter inviting Hercules Capital to finalize its application process to obtain a license to form and operate a third small business investment company subsidiary.

June 8, 2020 Hercules Capital | Scott Bluestein | Small Business Administration Phil Neuffer

Hercules Capital Provides $100MM Credit Facility to G1 Therapeutics

Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.

June 2, 2020 Armentum Partners | Bryan Jadot | G1 Therapeutics | Hercules Capital | Mark Velleca Phil Neuffer

RBC, Umpqua, Others Close $400MM Facility for Hercules Capital

Hercules Capital has replaced its existing $200 million credit facility with MUFG Union Bank with a new $400 million credit facility.

February 20, 2020 FSB | Goldman Sachs | Hercules Capital | MUFG | Royal Bank of Canada | TIAA | Umpqua Bank nadine

Hercules Provides Up to $100MM Facility for ChemoCentryx

ChemoCentryx has secured a credit facility of up to $100 million provided by Hercules Capital.

January 10, 2020 ChemoCentryx | Hercules Capital nadine

Sumitomo Provides $300MM Term Loan to Urovant

Urovant Sciences has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma, a global Japanese pharmaceutical company.

December 31, 2019 Hercules Capital | Sumitomo Dainippon Pharma | Urovant Sciences nadine

Hercules Capital Amends Axovant Facility

Axovant Gene Therapies amended its loan and security agreement with Hercules Capital.

December 3, 2019 Axovant Gene Therapies | Hercules Capital nadine

Hercules Capital Taps Bluestein as President/CEO

Hercules Capital has appointed Scott Bluestein as its chief executive officer and president, effective immediately.

July 18, 2019 Hercules Capital | Scott Bluestein nadine